<DOC>
	<DOCNO>NCT01951326</DOCNO>
	<brief_summary>The investigator hypothesize RHB-104 great efficacy placebo Crohn 's disease .</brief_summary>
	<brief_title>Efficacy Safety Anti-MAP Therapy Adult Crohn 's Disease</brief_title>
	<detailed_description>A Randomized , Double Blind , Placebo-controlled , Multicenter , Parallel Group Study Assess Efficacy Safety Fixed-dose Combination RHB-104 Subjects Moderately Severely Active Crohn 's Disease .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Inclusion Criteria 1 . Signed fully inform consent provide per protocol . 2 . Diagnosis Crohn 's Disease confirm endoscopy radiography and/or histology least 6 month prior randomization study . 3 . CD involve ileum and/or colon 4 . Moderately severely active CD ( Crohn 's Disease Activity Index ( CDAI ) score less equal 220 less equal 450 ) baseline . 5 . Current treatment least one follow therapy : A . Oral 5acetyl salicylic acid ( 5ASA ) compound . Dose must stable least 4 week baseline . B. Corticosteroid therapy . Dose must stable least 2 week baseline . C. Azathioprine 6mercaptopurine ( 6MP ) methotrexate . Dose must stable least 8 week baseline . D. Infliximab adalimumab . Dose must stable least 14 week baseline . 6 . White blood cell count great equal 3.5 x 109 screening . 7 . Active Crohn 's disease , define least one following : Creactive protein great Upper Limit Normal ( ULN ) screening , fecal calprotectin great Upper Limit Normal ( ULN ) screening , OR radiographic ( MRE CTE ) endoscopic confirmation presence active CD within 5 week screen visit . . 8 . Subject agree use barrier contraceptive method ( i.e . diaphragm , cervical cap , contraceptive sponge condom ) spermicidal foam/gel/cream/suppository , IUD/IUS progestogen injection ( DepoProveraÂ® ) throughout study least 6 week last study drug administration , unless subject postmenopausal otherwise incapable become pregnant reason surgery tubal ligation , vasectomy . In region local regulatory contraceptive requirement differ , ICF reflect local policy . Exclusion Criteria 1 . Crohn 's Disease involvement isolate mouth , upper gastrointestinal tract , anus . 2 . History total colectomy ileorectal anastomosis proctocolectomy . 3 . Presence active fistulizing Crohn 's Disease heal fistula within 2 month prior screen . 4 . Subject postoperative stoma , ostomy , ileoanal pouch . 5 . Subject short bowel syndrome . 6 . Subject schedule surgical bowel resection . 7 . Subject know symptomatic obstructive stricture bowel perforation 6 month prior screen . 8 . Change dose discontinuation oral 5acetyl salicylic acid ( 5ASA ) compound less 4 week prior baseline . 9 . Change dose discontinuation corticosteroid less 2 week prior baseline . 10 . Change dose discontinuation azathioprine , 6mercaptopurine ( 6MP ) methotrexate le 8 week prior baseline . 11 . Change dose discontinuation infliximab adalimumab le 14 week prior baseline . 12 . Treatment vedolizumab le 120 day prior baseline biological therapy ( apart infliximab adalimumab ) less 60 day prior baseline . 13 . Previous treatment rifabutin and/or clofazimine . 14 . Oral parenteral antibiotic 4 week prior baseline ( topical antibiotic permit ) . 15 . Treatment probiotic ( exclude yogurt yogurtderived product ) 4 week prior baseline . 16 . Females positive pregnancy test lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>moderate severe</keyword>
	<keyword>remission</keyword>
	<keyword>MAP</keyword>
	<keyword>antibiotic</keyword>
</DOC>